Table 3.
Estimated declines in GFR by combined baseline urinary protein-to-creatinine ratio and BP status
| Baseline Up/c | Normotensive (BP < 90th Percentile) (n=358) | Elevated BP (BP ≥90th Percentile) (n=164) | ||||
|---|---|---|---|---|---|---|
| Patients (n) | Median (IQR) Baseline GFR (ml/min per 1.73 m2) | Mean Change in GFR (ml/min per 1.73 m2 per yr) (95% CI)a | Patients (n) | Median (IQR) Baseline GFR (ml/min per 1.73 m2) | Mean Change in GFR (ml/min per 1.73 m2 per yr) (95% CI)a | |
| <0.5 | 229 | 53 (42, 69) | −0.8 (−1.2 to −0.4) | 94 | 58 (44, 71) | −1.9 (−2.5 to −1.2) |
| ≥0.5 | 129 | 39 (29, 51) | −1.8 (−2.4 to −1.2) | 70 | 40 (30, 49) | −1.7 (−2.4 to −1.0) |
| P value for difference | <0.001b | 0.01a | <0.001b | 0.77a | ||
Test for heterogeneity of association between baselineUp/c and GFR change by BP status: P=0.08.95% CI.
a
Estimates of change in GFR and reported P values derived from multivariable linear mixed-effects model adjusting for baseline Up/c, baseline BP status, baseline age, sex, race, current BMI z-score, and current angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker use.
b
Derived from Wilcoxon rank-sum test.